News | December 27, 2012

Biotronik Announces First U.S. Implants of its Bare Metal Stent

Company moves forward with IDE trial to enter U.S. market

December 27, 2012 — Biotronik announced that the first implant has taken place in the BIOHELIX-I trial in the United States. The BIOHELIX–I trial is set to evaluate the safety and performance of the Pro-Kinetic Energy coronary bare metal stent. The first implant was successfully performed by H. Barrett Cheek of Carolina Cardiology Cornerstone at High Point Regional Hospital in High Point, N.C.

The BIOHELIX-I trial is a prospective, nonrandomized, multicenter, investigational device exemption (IDE) study that will utilize Biotronik’s Pro-Kinetic Energy coronary stent system in patients with symptomatic, ischemic heart disease. More than 300 patients will be enrolled in the study, which is registered on www.clinicaltrials.gov.

Saurabh Gupta, M.D., director of the cardiac catheterization laboratory at Oregon Health & Science University in Portland, Ore., is the national principal investigator of the BIOHELIX-I study. “The thin cobalt chromium struts of the Pro-Kinetic Energy allow for greater flexibility and a reduced crossing profile, which translates into a highly deliverable stent,” Gupta said.

He added, “The clinical safety and performance of the Pro-Kinetic Energy stent has been demonstrated in recent results of the ENERGY registry, presented at the TCT 2012 conference. The BIOHELIX-I study will provide additional insight and experience into the clinical application of the Pro-Kinetic Energy stent for patients with ischemic heart disease.”

The Pro-Kinetic Energy is a thin strut (60?m/0.0024 inches) cobalt chromium, bare metal stent, completely sealed with a thin layer of amorphous silicon carbide called PROBIO. This passive coating is designed to reduce the amount of ions released from the stent, potentially reducing adverse reactions post-implantation.

The ENERGY registry was an all-comers registry of more than 1,000 patients with a complex population of 39 percent B2/C lesions and 46 percent acute coronary syndrome patients. At 12 months, Pro-Kinetic Energy showed a low 8.8 percent rate of major adverse cardiac events (MACE), including a 3.4 percent rate of target lesion revascularization (TLR). A subgroup analysis showed similarly low 12-month MACE rates in acute coronary syndrome (ACS) patients, elderly patients, and patients with small vessels or diabetes.

“Biotronik is very pleased to offer this state-of-the-art coronary stent technology to U.S. patients enrolled in the BIOHELIX study,” said Mark Johnson, program director for Biotronik’s U.S. vascular intervention business. “The Pro-Kinetic Energy provides both patients and clinicians with an optimal choice for their coronary vascular therapy needs.”

For more information: www.biotronik.com

Related Content

Societies Issue New Performance and Quality Measures for Treating Patients with Heart Attack
News | Cath Lab| October 17, 2017
The American College of Cardiology and the American Heart Association recently released updated clinical performance...
First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Dee Dee Wang runs Henry Ford Hospital's 3D printing lab for its complex structural heart cardiology program.

Dee Dee Wang, M.D., runs Henry Ford Hospital's 3-D printing lab that supports its complex structural heart program.

Feature | 3-D Printing| October 13, 2017 | Dave Fornell
Three-dimensional (3-D) printed anatomic models created from a patient’s computed tomography (CT), magnetic resonance...
Low Mortality and Stroke Risks Displayed for Minimally Invasive Aortic Valve Replacements
News | Heart Valve Technology| October 11, 2017
An analysis of more than 1,000 minimally invasive aortic valve replacements and more than 400 additional associated...
New Evaluation Sends Low-Risk ER Chest Pain Patients Home Sooner
News | Cardiac Diagnostics| October 10, 2017
A new evaluation to determine whether emergency room patients with chest pain can go home and follow up with their...
Videos | Chronic Total Occlusion (CTO)| October 09, 2017
Bill Lombardi, M.D., director of complex coronary artery interventions at the University of Washington, discusses the
BTG Acquires Roxwood Medical
News | Business| October 05, 2017
BTG plc announced it has acquired Roxwood Medical, provider of advanced cardiovascular specialty catheters used in the...
TVA Medical Receives CE Mark for Next-Generation EverlinQ 4 EndoAVF System
News | Vascular Access| October 04, 2017
TVA Medical Inc. announced that its everlinQ 4 endoAVF System has received CE Mark in the European Union. The...
News | Pharmaceuticals| October 04, 2017
October 4, 2017 — MyoKardia Inc.
Reflow Medical's Wingman Crossing Catheter Receives FDA Clearance for Coronary Indication
News | Catheters| October 02, 2017
October 2, 2017 — Reflow Medical Inc. announced that the company has received 510(k) clearance from the U.S.
Overlay Init